Gilead shot prevents all HIV cases in trial

Original Article ↗ Hacker News Discussion ↗

A phase 3 trial of Gilead’s twice‑yearly injectable HIV prevention drug lenacapavir in young women in South Africa and Uganda reported zero infections, outperforming existing daily PrEP pills like Truvada. Commenters explore how the trial was run ethically without a placebo arm, note that the shot is an antiviral rather than a vaccine, and weigh its potential to dramatically reduce HIV transmission against concerns over cost, access in poorer countries, long‑term safety, and public trust in pharmaceutical companies.

Trial design, ethics, and results

  • PURPOSE 1 is a Phase 3, double‑blind, randomized PrEP trial in ~5,300 cis women/adolescent girls (16–25) across South Africa and Uganda.
  • Participants were randomized 2:2:1 to:
    • Twice‑yearly subcutaneous lenacapavir
    • Daily oral Descovy
    • Daily oral Truvada
  • Because effective PrEP already exists, a placebo/no‑PrEP arm was considered unethical. Background HIV incidence (“bHIV”) and Truvada served as comparators.
  • Reported outcomes: 0 HIV infections among 2,134 on lenacapavir vs 16 among 1,068 on Truvada; lenacapavir superior to both bHIV and Truvada with very low incidence and p<0.0001.
  • Participants were already sexually active, instructed to live as usual, and not deliberately exposed to HIV. High local prevalence makes incident infections statistically expected in controls.

Mechanism, dosing, and adherence

  • Lenacapavir is a capsid inhibitor used in HIV treatment; here it’s used as long‑acting PrEP.
  • Commenters stress this is not a vaccine but prophylactic antiviral therapy, analogous to existing oral PrEP but with much longer dosing intervals (every 6 months vs daily).
  • Large adherence benefits are anticipated: easier for people who struggle with daily pills, face stigma, have controlling partners, or costly clinic access.
  • Questions raised about how rigid the 6‑month schedule must be (e.g., 7 months) and what happens if someone stops after having had subclinical infections; this remains unclear in the discussion.

Safety, cost, and access

  • One commenter links to side‑effect listings, suggesting tolerability in healthy people needs scrutiny, especially for mass prophylaxis.
  • Others note it will likely be expensive under patent and only become broadly cheap after expiry, unless subsidized programs intervene.
  • There is significant concern about equity: Africa as a historical site of unethical trials, IP barriers, and whether high‑risk populations in poorer countries will actually get the drug.

Social and behavioral dimensions

  • Several posts emphasize social context: gender‑based violence, rape, and power imbalances in relationships driving women’s HIV risk.
  • Some women reportedly use PrEP secretly to protect themselves without provoking accusations of infidelity.
  • Parallel debates on condoms vs PrEP highlight that multiple overlapping methods are valuable; adherence, pleasure, and real‑world behavior all matter.

Broader reflections

  • Many commenters express excitement that this could be a major step toward controlling or even eventually eradicating HIV, if scaled globally.
  • Others temper this with skepticism about pharma behavior, trial framing (100% efficacy claims), and broader distrust fueled by past corporate and public‑health failures.